Posted by Michael Wonder on 13 Dec 2017
New concentrated insulin approved and available for Canadian patients
12 December 2017 - Entuzity KwikPen is five times more concentrated than the current option.
Eli Lilly Canada is pleased to announce the Health Canada approval and availability of Entuzity KwikPen (insulin human biosynthetic 500 units/mL) for the treatment of adults and children with diabetes requiring insulin.
Entuzity is intended for insulin-resistant patients with diabetes requiring daily doses of more than 200 units, as it allows a large dose to be administered subcutaneously in a smaller volume.
